Patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC) with central nervous system (CNS) disease had longer overall survival (OS) and decreased mortality risk compared with those who have extracranial metastasis, according to study results published in JAMA Network Open. The findings suggest that aggressive local and systemic therapies may be needed to control the intracranial progression of CNS metastases.
Malignant tumors on a brain | Image Credit: © Nima | stock.adobe.com
Brain metastasis is a common complication of HER2+ breast cancer that affects an estimated 30% to 35% of patients with advanced disease. Advancements in treatments have yielded deeper responses and significant survival benefits, improving outcomes for patients. Combined targeted treatments, such as…